122,718 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Bought by Wellington Wealth Strategies LLC.

Wellington Wealth Strategies LLC. acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 122,718 shares of the company’s stock, valued at approximately $41,000.

Other institutional investors also recently bought and sold shares of the company. Paloma Partners Management Co acquired a new position in shares of Ginkgo Bioworks during the first quarter worth about $28,000. First Trust Direct Indexing L.P. purchased a new position in shares of Ginkgo Bioworks during the 1st quarter worth approximately $35,000. Russell Investments Group Ltd. lifted its holdings in shares of Ginkgo Bioworks by 9,440.6% in the 1st quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock valued at $37,000 after buying an additional 31,626 shares during the period. Smith Salley Wealth Management grew its holdings in Ginkgo Bioworks by 125.0% during the first quarter. Smith Salley Wealth Management now owns 54,000 shares of the company’s stock worth $63,000 after acquiring an additional 30,000 shares during the period. Finally, Algert Global LLC acquired a new position in Ginkgo Bioworks during the second quarter worth $36,000. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

NYSE:DNA opened at $8.09 on Monday. The firm has a market cap of $17.89 billion, a PE ratio of -18.39 and a beta of 1.06. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $75.20.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. The company had revenue of $56.21 million for the quarter, compared to the consensus estimate of $41.46 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. BTIG Research boosted their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. TD Cowen boosted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. Finally, The Goldman Sachs Group dropped their target price on shares of Ginkgo Bioworks from $0.02 to $0.01 and set a “sell” rating for the company in a report on Tuesday, July 9th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.42.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.